EP-1391: EGFR/ALK Mutations in Stage III Non-small Cell Lung Cancer Patients Received Chemoradiotherapy
نویسندگان
چکیده
منابع مشابه
Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical resection. Surgery alone has long been recognized as insufficient for this stage, and thus neoadj...
متن کاملConcurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
PURPOSE Combined chemoradiotherapy is standard management for locally advanced non-small cell lung cancer (LA-NSCLC), but standard treatment for elderly patients with LA-NSCLC has not been confirmed yet. We evaluated the feasibility and efficacy of concurrent chemoradiotherapy (CCRT) for elderly patients with LA-NSCLC. MATERIALS AND METHODS Among patients older than 65 years with LA-NSCLC, 36...
متن کاملDurvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
BACKGROUND Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progressi...
متن کاملConcurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
Over the last two decades, several approaches to multimodality therapy have been investigated in patients with advanced unresectable non-small cell lung cancer. These include induction chemotherapy and concurrent chemoradiotherapy. Both approaches have been shown to be superior to radiation therapy alone. However, in several randomized trials, concomitant chemoradiotherapy was shown to be super...
متن کاملOutcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity.
BACKGROUND published trials of concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) generally excluded patients with significant comorbidity. We evaluated outcomes in patients who were selected by using radiation planning parameters and were considered, despite comorbidity, fit enough to receive cisplatin-based chemotherapy. PATIENTS AND METHODS from 2003 to 200...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiotherapy and Oncology
سال: 2018
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(18)31700-6